BioPharm America™ 2015 Program Overviewwww.ebdgroup.com/bpa/program
|Monday, September 14, 2015|
Level 3, Atrium
BioPharm America™ 2015 Welcome Reception
You will be able to pick up your name badge at the welcome reception.
|Tuesday, September 15, 2015|
The perfect pitch: Do you have what it takes to win over investors?
What you have to say in 30 seconds could mean the difference between a meeting with an investor and a door closed in your face. Win a one-to-one meeting with a leading life science private equity investor.
Members of the audience will have 30 seconds to give their elevator pitch to a star-studded panel of seasoned industry investors. The top picks will be selected for a second round that includes two minutes of presentation and/or Q&A time with the judges. First- and second-place winners will receive a full 30-minute private follow-up meeting with the panelist of their choice. Judges will receive a written summary of all participant pitches and their scores, should they wish to follow up on their own. All are welcome: entrepreneurs, service providers, job seekers, executives and more.
Audience preparation notes:
Big data: Going from buzzword to business
From genomics to drug discovery to compliance, the amount of data the biopharma industry has the ability collect and analyze is staggering. But, there are many questions to be addressed: How can we effectively mine the data to make impactful decisions in R&D? What information is being assessed by payers? Why are certain areas of biotech getting funded where others are not? This panel will address these questions and discuss how big data is being used to help companies more efficiently design clinical studies, enroll targeted patients, and ultimately help drive strategic business decisions.BioPharm America™ 2015
Pharma and Large Biotech Presentations
|10:45 am–12:30 pm||
Welcome and Opening Plenary Discussion
Opening Plenary Discussion
Giving up the corporate jet and going back to the trenches: Insights from biotech disrupters
There is an increasing number of industry heavy hitters who have successfully led and exited large corporations and are now investing their experience, clout and in some cases, personal finances to reseed the life science ecosystem by leading the charge at small companies. Join us as they provide their perspectives from both sides of the fence, share the "war stories" that got them to where they are, and discuss how their experiences are helping them drive innovative small companies to successfully attack difficult targets at the front lines.
Senior Managing Director
Parallel Panel Discussions
Dealmaking and Strategy
Rare diseases: The new norm?
With over 7,000 rare diseases and treatments for only 5% of them, the need for cures is obvious. With that need comes great opportunities—and risks—for drug developers. Though the therapeutic promises for the treatments of rare diseases are greater now than ever before, significant hurdles are in the way of getting patients access to innovative therapies. Heads of leading R&D companies and patient organizations will share their insights on the evolving landscape and discuss the importance of patient engagement and cross-sector collaborations in addressing the opportunities and challenges in financing, clinical trials, pricing, and patient access.BioPharm America™ 2015
Externalizing R&D, building efficient pharma
While attempting to maintain a continuous number of potential products, big pharma has had to adjust their acquisition and investment strategy due to declining R&D productivity in recent years. This has resulted in a significant shift from internal to external R&D, allowing industry to focus on scouting the most promising developments in biotech. The panel will discuss what is unique to their individual searches and how they prioritize.
Instant biotech: Creating a clinical-stage startup by in-licensing assets
With numerous acquisitions and mergers among big pharma, and more programs from academics and biopharma than investors are willing to fund, many innovative, clinical-stage products that don't fit the mold are being left on the shelf. This leaves entrepreneurs in a perfect position to create startup companies with an instant pipeline. The panelists will discuss the multitude of options available when creating a biotech company by in-licensing assets, as well as their strategy on securing funding and the difficulties along the way.BioPharm America™ 2015
Off the Record Roundtables
How can we improve the outcome of non-dilutive funding?
There is a wide gap between what's being funded by the NIH and what actually gets to market. Why is this happening and what can industry do to improve it? Join this roundtable as we discuss the ways in which non-dilutive funding and industry can align to produce better outcomes.BioPharm America™ 2015
Digital health is steadily growing and providing advances in the way health data is collected, organized and analyzed, which will influence patient treatment plans of the future. In years to come doctors may not only prescribe medicine, but also recommend a digital program for treatment. This panel will discuss how digital health has the potential to change the way therapeutics companies incorporate digital health into overall patient treatment strategies.BioPharm America™ 2015
How does pharma get involved in an outside-the-box idea?
Every pharma company boasts about being innovation-driven, yet the majority of their R&D targets and approaches are in the same five therapeutic areas. Sit down with executives from pharma going after the white space areas to discuss why going into these overlooked areas alone can actually be wildly successful.BioPharm America™ 2015
Biomarkers and precision medicine
Advancements in biomarkers and precision medicine have the potential to radically change disease treatment and prevention. With greater understanding of individual patient information, more targeted and tailored treatment options are available. Panelists will discuss how the future of biomarkers and personalized medicine will impact R&D decisions and ultimately benefit patients.BioPharm America™ 2015
One-to-one Meetings ►
Evening Networking Reception
|Wednesday, September 16, 2015|
Pharma and Large Biotech Presentations
|8:00 am–6:00 pm
One-to-one Meetings ►
|10:00 am–12:45 pm||
Alternative partners roundtable
Clear methods are in place for how to approach pharma and even traditional investors but how do you get to the alternative partners that can make or break your startup? Venture philanthropists, patient groups, foundations and institutes discuss the best methods for getting the attention of all the other players.Discussion leader:
Hear directly from your potential deal partners (large and small): What are they are looking for? Where do they source from? How do you get their attention? Execs from the leading pharma companies will share "dos and don'ts" and other helpful advice going into your afternoon pitches.BioPharm America™ 2015
Investors with backgrounds in traditional venture capital, angel investing, and venture philanthropy will highlight innovative financing methods for early stage companies. Building relationships and perfecting your pitch are keys to securing funding, so panelists will also discuss when and how to approach investors with your business proposition.Discussion leader:
Afternoon pitches by startup companies
Pitch your startup to a panel of judges comprising BD execs, venture capitalists, and industry experts!
Qualifying startup companies are invited to pitch their company using no more than four slides (or no slides if you dare!) in four minutes. Our top-notch panel of judges will determine the winner by the quality and effectiveness of the pitch.
|1:30–4:30 pm||Company Presentations ►|
|Thursday, September 17, 2015|
|8:30 am–12:30 pm||Company Presentations ►||8:00 am–3:00 pm
One-to-one Meetings ►
Opening Panel Discussion
The evolution of the Regen Med ecosystem: What's required for its growth and sustainability?
The Boston area is rich with innovative Regen Med companies and flush with cash from investors but is that enough? It takes more than hot technologies to build a viable business and more importantly, make an impact in patients' lives. What does the Regen Med/Cell and Gene Therapy sector need to become sustainable long-term? Panelists will discuss the need for an integrated approach to building the necessary infrastructure for success and help define the critical roles of startups, established biopharma, clinicians, manufacturers, and other stakeholders that can make or break this maturing industry.BioPharm America™ 2015
|10:30 am–12:45 pm||
Gene and cell therapy
With breaking headlines on how gene therapy can transform the way we treat diseases, the sector is booming. This panel will discuss the latest industry advances, new partnerships, regulatory issues, and other exciting developments.BioPharm America™ 2015
We have seen exciting progress in the field of gene editing but how are these advances being applied to cell therapy and disease modification? How are techniques used in the lab like CRISPR and TALENS being translated to real benefits in patients, especially those with heredity diseases? In addition to the scientific advances, what regulatory issues will need to be addressed before we can see treatments? What can we expect to see in the near and long-term?BioPharm America™ 2015